Heartflow's AI Plaque Analysis software leads to significant improvements in cholesterol management and cardiac risk reduction in coronary artery disease patients.
Key Details
- 1DECIDE Registry, the largest prospective study of its kind, enrolled ~20,000 CAD patients at 30+ US clinical sites.
- 2Heartflow AI Plaque Analysis prompted treatment changes in over 50% of patients versus CCTA alone.
- 3Patients managed using the software saw mean LDL cholesterol reductions of 18.7 mg/dL.
- 4A 15% estimated reduction in cardiac event risk was observed for these patients.
- 5Significant management changes occurred even in patients with no calcified plaque.
- 6The AI provides individualized risk insights by quantifying and characterizing all plaque types, including non-calcified, soft plaques.
Why It Matters
This large-scale prospective evidence demonstrates that adding AI-based plaque quantification to CCTA can materially change patient management, with potential to reduce adverse cardiac events. These results highlight the growing role of imaging AI in personalizing cardiovascular care.
Source
Cardiovascular Business
Related News
•Radiology Business
Lucida Medical Raises $11M for AI-Based Prostate MRI Diagnosis Expansion
Lucida Medical, specializing in AI-assisted prostate cancer diagnosis via MRI, raises $11.4M to drive US FDA approval and platform expansion.
•Radiology Business
Real-World Trial: AI Tool Cuts Radiologist Workload in Mammography
A prospective study shows AI can safely reduce radiologists’ workload and increase cancer detection in breast cancer screening.
•AuntMinnie
AI Mammography Tool Shows No Significant Benefit in Single-Reader U.S. Study
A real-world study found no significant improvement in breast cancer detection or recall rates with an FDA-approved AI mammography tool in a single-reader setting.